Las Vegas Sands Corp. vs Teladoc Health Inc — how do they compare? Las Vegas Sands Corp. trades at $45.62 (market cap $30.36B), while Teladoc Health Inc trades at $9.72 (market cap $1.74B). The key difference: Las Vegas Sands Corp. is far larger — about 17.4× Teladoc Health Inc's market cap, and Las Vegas Sands Corp. pays a 2.4% dividend while Teladoc Health Inc pays none. Which is the better fit depends on your goals.
| LVS | TDOC | |
|---|---|---|
Market Cap | $30.36B | $1.74B |
Sector | Consumer Cyclical | Health |
52-Week High | $69.49 | $9.72 |
52-Week Low | $44.78 | $4.47 |
Enterprise Value | $42.75B | $2.03B |
Dividend Yield | 2.4% | — |
Signals from Pluang's Aura AI — not financial advice
LVS trades at $45.66, up 0.66% on the day, with a bearish technical signal but strong fundamentals. Recent quarters show consistent earnings beats, with Q1 2026 EPS of $0.91 beating expectations. Revenue growth is robust, reaching $13.02B in 2025, and profitability metrics like a 49.59% gross margin and 94.53% ROE are impressive. The company maintains positive cash flow and recently paid a $0.30 dividend. Analyst sentiment is bullish with a $65.18 consensus price target, though technical indicators suggest near-term pressure.
The outlook for LVS is positive based on fundamental strength and analyst optimism, but risks include high debt levels and bearish technical trends. Investment opportunity lies in its earnings momentum and valuation upside, while investors should monitor debt management and market volatility. The stock's current price near support levels may present a entry point if fundamentals hold.
TDOC trades at $9.63, up 2.12% today, with a bullish technical signal from moving averages and a neutral RSI near 60. Revenue remains stable around $2.5 billion, but net losses persist with a -6.81% margin. Recent news highlights expansion through the Walmart partnership and upcoming Q2 2026 earnings. The stock shows resilience despite negative profitability, supported by a low P/S ratio of 0.67 and improving cash flow trends from operations.
Outlook is mixed: cost-cutting and partnerships offer growth potential, but sustained losses and high debt pose risks. Analysts are cautious with a $8.75 price target below current levels, reflecting concerns over profitability. Investors should weigh the recovery narrative against financial challenges, with earnings on July 29, 2026, as a key catalyst.
Trailing returns across standard periods
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.
Read more on LVS →Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →